The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

On a YTD basis, U.S. trade was a record $1.94 trillion, exports a record $711.20 billion, imports a record $1.22 trillion, ...

Prescription drug cost barriers are increasingly causing people to divert from doctor-recommended treatment plans.

Nintendo's Switch 2 launches to overwhelming demand and limited supply. Analysts predict strong early sales and long-term ...

Friedrich Merz is the latest in a string of European leaders who have traveled to the White House in recent weeks in a coordinated campaign to cajole Trump into backing new sanctions on Russia, ...